Figure 2.

Enhanced therapeutic response in the loss of secreted gelsolin settings is dependent on DNGR-1. (A) Tumor growth profile in mice bearing MCA-205 fibrosarcoma receiving chemotherapy. Doxorubicin was administered to cohoused WT (n=10), sGsn^–/– (n=10) and sGsn^–/– Clec9a^gfp/gfp (n=10) mice, and compared with cohoused WT (n=10), sGsn^–/– (n=3) and sGsn^–/– Clec9a^gfp/gfp (n=3) mice receiving vehicle control. (B) Growth profile of B16-F10 LA-OVA-mCherry melanoma in co-housed WT (X-ray, n=14; sham, n=10), sGsn^–/– (X-ray, n=11; sham, n=10) and sGsn^–/– Clec9a^gfp/gfp (X-ray, n=12; sham, n=11) mice. Data are plotted as tumor volume (mm³) $\pm$SEM, and mean tumor volumes were compared using two-way ANOVA with post hoc Bonferroni correction. Where indicated, *p$\le$0.05, **p<0.01, ***p<0.001, ****p<0.0001; NS, not significant. Error bars are depicted in all plots; when not visible, errors are small. Data are representative of one experiment respectively. ANOVA, analysis of variance; LA, LifeAct; OVA, ovalbumin; WT, wild type.